<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333433</url>
  </required_header>
  <id_info>
    <org_study_id>INN005 - EXT</org_study_id>
    <nct_id>NCT04333433</nct_id>
  </id_info>
  <brief_title>PRESERFLO® MicroShunt Extension Study</brief_title>
  <official_title>A Prospective, Concurrent Controlled, Open-Label, Multicenter Clinical Study to Assess the Long-Term Safety of the PRESERFLO® MicroShunt in Subjects With Primary Open-Angle Glaucoma Who Have Completed Participation in the INN-005 Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnFocus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnFocus Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, concurrent controlled, open-label, multicenter study is designed to collect
      additional safety data through 5 years of follow-up for subjects randomized to either the
      treatment arm (PRESERFLO® MicroShunt with MMC) or the control arm (Trabeculectomy with MMC)
      of the INN-005 clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the long-term safety of the PRESERFLO® MicroShunt
      in subjects with Primary Open-Angle Glaucoma who have completed their Month 24 Follow-Up
      Visit in the INN-005 clinical study, by collecting safety data through 5 years post-operative
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of sight-threatening adverse events</measure>
    <time_frame>Through 5 years postoperative follow-up</time_frame>
    <description>Incidence of sight-threatening adverse events, including but are not limited to events such as endophthalmitis, corneal decompensation, severe retinal detachment, severe choroidal hemorrhage, severe choroidal detachment, and aqueous misdirection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>MicroShunt treatment group</arm_group_label>
    <description>Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 were implanted with the device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy control arm</arm_group_label>
    <description>Subjects previously randomized to this arm in pivotal study conducted under IDE G130028 underwent trabeculectomy procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRESERFLO® MicroShunt</intervention_name>
    <description>Device surgically implanted</description>
    <arm_group_label>MicroShunt treatment group</arm_group_label>
    <other_name>InnFocus MicroShunt® Glaucoma Drainage System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.</description>
    <arm_group_label>Trabeculectomy control arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes all living subjects who have completed the Month 24 Follow-Up
        Visit of the INN-005 clinical study after randomization to either the PRESERFLO® MicroShunt
        treatment arm or the Trabeculectomy control arm, and who are willing and able to extend
        their study participation and return for up to three (3) additional annual follow-up visits
        through post-operative Month 60. Up to 629 subjects may be enrolled at up to 24 sites
        located in the United States and at up to 5 sites located in Europe
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has completed their Month 24 Follow-Up Visit in the INN-005 clinical study
             conducted under IDE G130028.

          2. Subject was randomized into the INN-005 study and received the PRESERFLO® MicroShunt
             device or trabeculectomy. (Subjects who have had the device explanted, or replaced
             with another device, may be included).

          3. Subject is willing and able to comply with all study requirements, including signing
             an informed consent form.

        Exclusion Criteria:

        1. Subject has exceeded the timeframe for the Month 60 Follow-Up Visit prior to enrollment
        for participation in this long-term follow-up study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Paul Palmberg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bascolm Palmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Advance Eye Research Institute, LLC.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Eye Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Connecticut</name>
      <address>
        <city>Meriden</city>
        <state>Connecticut</state>
        <zip>06450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Eye Center</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugene and Marilyn Glick Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiles Eye Care Excellence &amp; Glaucoma Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, PA</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Consultants of the Capital Region</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Surgeons and Consultants of Ohio</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Partners of Pennsylvania</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R&amp;R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Ophtalmologique de la Clinique Mutualiste</name>
      <address>
        <city>Pessac</city>
        <state>Bordeaux</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Ophtalmologique de la Clinique Mutualiste</name>
      <address>
        <city>Pessac</city>
        <state>Bordeaux</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O.U.P (Azienda Ospedaliere Universitaria Pisana) Stabilimento di Cisanello</name>
      <address>
        <city>Pisa</city>
        <state>Cisanello</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POAG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

